The podcaster behind ‘Drug Story’ on public-health storytelling

Thomas Goetz, the journalist and author behind the podcast "Drug Story," joined the First Opinion Podcast to discuss how narrative storytelling can reshape public understanding of the pharmaceutical industry and its impact on American health.

Goetz, who previously served as executive editor at Wired and authored the book "The Remedy," has built Drug Story around a premise that most pharma coverage gets wrong: it's not just about prices and patents, it's about the human stories embedded in how drugs are discovered, tested, marketed, and prescribed. The podcast digs into the gap between what Americans expect from their medications and what the system actually delivers.

The conversation touched on a central tension in health communication. Americans spend more on prescription drugs per capita than any other nation, yet surveys consistently show low trust in pharmaceutical companies. Goetz argues that this distrust stems partly from how little the public understands about what goes into making a drug — the years of research, the clinical trial failures, the regulatory negotiations — and partly from genuine failures of transparency when companies prioritize shareholder returns over patient outcomes.

Drug Story's approach is to make the science accessible without dumbing it down, and to hold companies accountable without defaulting to cynicism. The podcast has gained traction at a moment when public health messaging is under unprecedented scrutiny, from pandemic response to the opioid settlement aftermath to the growing debate over drug pricing legislation.

What This Means For You: Health literacy is becoming a survival skill. Podcasts like Drug Story are filling a gap that traditional media has largely abandoned — explaining how the pharma system actually works, in language regular people can follow. If you've ever felt confused by drug pricing, FDA approvals, or why your insurance covers one medication but not another, storytelling-driven health journalism is worth your time. It won't lower your copay, but it might help you understand why it's that high in the first place.